Ma­gen­ta sets up Di­anthus merg­er in quick, three-month about-face af­ter end­ing tri­al due to pa­tient death

Ma­gen­ta Ther­a­peu­tics will give its spot on Nas­daq to pri­vate­ly-held Di­anthus Ther­a­peu­tics af­ter a pa­tient death spurred an end to Ma­gen­ta’s clin­i­cal work and an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER